標靶治療市場：腫瘤學

Targeted Therapeutics Report : Oncology

出版日期: 2023年11月01日 | 出版商:

Greystone Research Associates | 英文 125 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

利用新途徑和訊號傳導的十二種標靶療法已經取得了代表腫瘤學和抗腫瘤治療新時代的成果。透過這些方法，越來越多的藥物開發商正在尋求從減輕癌症帶來的身體、心理和情緒負擔的治療中獲利。

本報告調查了標靶治療藥物市場，研究了腫瘤臨床試驗的趨勢、50 種治療藥物及其使用的生物標記物，並依細分市場總結了趨勢。

執行摘要
重組藥物生態系統
標靶腫瘤治療市場領導者
腫瘤生物製劑 - 競爭考量
核准用於腫瘤標靶治療的藥物
FDA 核准的藥物
EMA 核准的藥物
曲妥珠單抗生物相似藥
EMA 核准的生物相似藥
訴訟對生物相似藥產品上市的影響
標靶腫瘤治療 - 細分市場
乳癌
大腸癌
血癌
肺癌
黑色素瘤
轉移性胃癌
神經系統癌症
腎細胞癌
尿路上皮癌
供應商競爭力評估

簡介目錄

Targeted Oncology Therapeutics is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug developers, and healthcare marketers with a detailed understanding of the economics, technologies, indications, and commercial opportunities for targeted oncology drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Next-generation Therapeutics

The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of cancer. This report examines the fifty therapeutic drugs and the biomarkers they utilize.

Here is a Small Sample of the Things You Will Learn:

How many suppliers have approved mAb products indicated for one or more types of lung cancer?
Who are the API suppliers for the EMA approved version of Adcetris?
How many approved biosimilars (FDA and/or EMA) are there for trastuzumab?
What is the number of EMA approved biosimilars for oncology indications?
Which Daiichi Sankyo facilities in Japan are used for the API and final manufacture of Enhertu?
How many approved mAbs are indicated for HER2-positive Breast Cancer?
Which two mAbs indicated for oncology are supplied as lyophilized powders for reconstitution?
How many approved oncology mAbs target the CD20 antigen?
Which supplier is the oncology mAb market leader in terms of revenue?